Alnylam Pharmaceuticals, Inc. (ALNY): Cash & Equivalents
$1.66B
As of 2025-12-31
$1.71B
As of 2026-06-30
+24.1%
3-year compound annual growth
+27.3%
5-year compound annual growth
+24.8%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.66B | +71.5% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $966.43M | +18.9% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $812.69M | -6.2% | 2026-02-12, Balance as of period end |
| 2022-12-31 | $866.39M | +5.7% | 2025-02-13, Balance as of period end |
| 2021-12-31 | $819.98M | +65.1% | 2024-02-15, Balance as of period end |
| 2020-12-31 | $496.58M | -9.2% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $547.18M | +30.2% | 2022-02-10, Balance as of period end |
| 2018-12-31 | $420.15M | -34.9% | 2021-02-11, Balance as of period end |
| 2017-12-31 | $645.36M | +233.3% | 2020-02-13, Balance as of period end |
| 2016-12-31 | $193.62M | +7.0% | 2019-02-14, Balance as of period end |
| 2015-12-31 | $180.90M | +140.6% | 2018-02-15, Balance as of period end |
| 2014-12-31 | $75.18M | +41.4% | 2017-02-15, Balance as of period end |
| 2013-12-31 | $53.17M | +3.4% | 2016-02-12, Balance as of period end |
| 2012-12-31 | $51.41M | -26.8% | 2015-02-13, Balance as of period end |
| 2011-12-31 | $70.23M | -5.9% | 2014-02-20, Balance as of period end |
| 2010-12-31 | $74.60M | -45.7% | 2013-02-19, Balance as of period end |
| 2009-12-31 | $137.47M | -28.3% | 2012-02-13, Balance as of period end |
| 2008-12-31 | $191.79M | n/a | 2011-02-18, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.66B | +71.5% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.39B | -42.3% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $1.31B | +39.1% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.56B | -8.3% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $282.03M | +155.1% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $545.00M | +16.5% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $4.55B | +73.1% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $618.70M | -33.4% |
| Organon & Co. (OGN) | 2025-12-31 | $574.00M | -15.0% |
Compare ALNY, JAZZ, BMRN, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗